LumeRx is a medical device company developing novel light-based therapies for the treatment of diseases caused by bacterial and other pathogenic infections. Its first device will deliver a specific wavelength of light to the stomach to eradicate h. pylori, the bacteria causing peptic ulcer disease (PUD) and believed to be the cause of gastric cancer.
Missing: LumeRx's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: LumeRx's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest LumeRx News
Aug 7, 2017
May, 2008 - LumeRx reported several events concerning its plans moving forward. Trial results analysis from work recently completed in India reveals current visible light approaches are not adequate as a primary treatment for H. Pylori. As a result of these findings, the Company's investors have decided to not invest further in LumeRx and to scale back operations. Jon McGrath has stepped down from his position as CEO with day-to-day responsibilities assumed by David Hendren of Catalyst Health Ventures. Catalyst and other investors are now considering the future course for the LumeRx. http://www.masshightech.com/stories/2008/05/26/weekly13-Future-is-unclear-as-LumeRx-shuffles-execs,-Gabrieli-ends-funding.html Posted by
LumeRx Frequently Asked Questions (FAQ)
Where is LumeRx's headquarters?
LumeRx's headquarters is located at 100 Locke Drive, Marlborough.
What is LumeRx's latest funding round?
LumeRx's latest funding round is Dead.
How much did LumeRx raise?
LumeRx raised a total of $8.19M.
Who are the investors of LumeRx?
Investors of LumeRx include Bessemer Venture Partners, Catalyst Health Ventures, Origin Partners, Echelon Ventures, Beacon Life Sciences and 3 more.
Who are LumeRx's competitors?
Competitors of LumeRx include HistoSonics, Aethlon Medical, Light Sciences Oncology, Cianna Medical, TRIA Beauty and 15 more.
Compare LumeRx to Competitors
Aethlon Medical is the developer of the Hemopurifier - medical device that aims to treat infectious disease.
Cardiogenesis is a medical device company committed to innovating tools for the treatment of cardiovascular disease. The company, located in Orange County, California, is a provider in laser revascularization and angiogenic therapies for the treatment of severe angina.
HistoSonics develops a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquefy unwanted tissue and tumors at sub-cellular levels. The company is focused on the development of its Edison platform, combining imaging with sensing technology to deliver personalized external beam treatments with precision and control, reducing the side effects of conventional therapies. The company was founded in 2009 and is based in Minneapolis, Minnesota.
Pathfinder Therapeutics (PTI) is the developer of Explorer, an image-guided "GPS" device that enables physicians to accurately and efficiently guide the delivery of cancer therapeutics (usually resection and/or ablation) in soft-tissue organs. Explorer is cleared by the FDA in the category of Intraoperative Soft Tissue Tracking. Scout, the company's advanced 3D planning software, provides highly detailed visual and volumetric information for preoperative assessment, thus enabling clinicians to visualize the site of disease, plan the resection and/or ablation and monitor the resultant effects.
Nexeon MedSystems is committed to improving lives through the development of therapies for people with cardiovascular disease. With proven medical device research and development talent, a strong intellectual property portfolio and the leadership of a veteran interventional cardiologist, Nexeon has created an pipeline of products for unmet clinical needs.
ADVOS is a combined multi-organ support system for liver, lung, kidney, and acid-base balance. Based on the principle of albumin dialysis, ADVOS allows both extracorporeal elimination of CO2, hepatic toxins, and water-soluble & protein-bound nephrotoxins, as well as the correction of metabolic and respiratory acidosis. The ADVOS procedure works with dialysis-usual access and flow rates and does not require a gas exchanger for CO2 elimination.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.